CVS wants payback from GMP violators; Genzyme sued for Fabrazyme rationing;

> CVS Pharmacy is demanding $100 million from KV Pharmaceutical, Ethex and Nesher Pharmaceuticals for halting the supply of generics in 2008 due to GMP failures. News

> Fabry disease sufferers have filed suit against Genzyme and Mt. Sinai Medical School, the developer and license holder of Fabrazyme, for their handling of the drug shortage. Story

> Regional drug-production hubs created via big pharma tech transfer can improve public health and drive economic development in low- to mid-income countries, says Eli Lilly. Article

> Sanofi has recalled nearly 200,000 doses of the ActHIB flu vaccine in Japan; users found foreign matter in the syringes after injection. Story

> Amgen will buy a Pfizer manufacturing plant at Dun Laoghaire, County Dublin, securing 280 jobs. Release

> In response to a new healthcare reform reimbursement policy, doctors are balking at writing prescriptions for OTC products and pharmacists are complaining about filling them. Item

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)